Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome.
OBJECTIVE
To compare the effects of different low-density lipoprotein (LDL) cholesterol-lowering statin treatments on small dense LDL (sd-LDL) in hypercholesterolemic patients with metabolic syndrome (MetS).


METHODS
Forty hypercholesterolemic MetS patients ?30 years of age were randomized to rosuvas-tatin (n=17) or other statins (n=23) groups. In the other statins group, those taking atorvastatin (n=12) were also evaluated separately. Statin doses were 10 mg/day rosuvastatin, 20 mg/day atorvas-tatin, 40 mg/day simvastatin, and 40 mg/day pravastatin. Treatment duration was planned to be 8 weeks. Sd-LDL levels were assessed at baseline and at the completion of treatment.


RESULTS
After treatment, sd-LDL levels were significantly reduced in all 3 groups (from 29.6+/-24.8 mg/dL to 8.9+/-8.5 mg/dL in the rosuvastatin group, p=0.001; from 26.2+/-15 mg/dL to 14.8+/-9.6 mg/dL in the atorvastatin group, p=0.02; and from 29.1+/-16.5 mg/dL to 14.7+/-11.2 mg/dL in the other statins group, p=0.0001). There was no significant difference in the mean percent changes among groups.


CONCLUSIONS
Significant reduction in sd-LDL levels was observed after 8 weeks of statin treatment in hypercholesterolemic patients with MetS. This effect was similar for all statins and can be considered a class effect.
Bahadir
Muzeyyen Aslan
MA
Internist, Goztepe Training and Research Hospital, Department of Internal Medicine, Turkey.
Oguz
Aytekin
A
Uzunlulu
Mehmet
M
Bahadir
Ozgur
O
D000328:Adult; D000886:Anthropometry; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL